Business · Companies · 1 hr ago
Roche agrees deal with Hansoh worth up to $15 billion
Roche has agreed to work with China-based Hansoh on developing antibody-drug conjugates, or ADCs.
Roche will pay $400 million upfront, and the deal could be worth up to $15 billion in total.
Hansoh will contribute two experimental ADCs that are still in preclinical development and develop other candidates against targets Roche proposes.
The companies have not said which drugs or diseases the partnership will focus on.
The agreement is Roche’s sixth deal in China since late August, reflecting a recent push to work with Chinese drugmakers.
The companies have not announced further details about the partnership’s next steps.
Roche agreed to a partnership with China-based Hansoh Pharmaceutical Group focused on antibody-drug conjugates.
Roche will pay $400 million upfront, and the deal could be worth up to $15 billion overall.
Hansoh will contribute two preclinical antibody-drug conjugates and develop others against targets proposed by Roche.
The companies did not specify the drugs or diseases involved.
The agreement is Roche’s sixth deal in China since late August, according to BioPharma Dive.
- Who
- Roche and Hansoh Pharmaceutical Group.
- What
- They agreed to a partnership focused on antibody-drug conjugates, worth up to $15 billion.
- When
- Monday, October 19, 2026, according to the articles.
- Where
- The deal is between Swiss drugmaker Roche and China-based Hansoh.
- Why
- Not stated.
This story does not have two clearly opposing sides.
Roche’s recent run of China deals began, according to BioPharma Dive.
Hansoh said Roche would pay $400 million upfront in a partnership that could be worth up to $15 billion.
- Upfront payment
- $400 million
- Potential total value
- Up to $15 billion
- Hansoh contribution
- Two preclinical antibody-drug conjugates
- Deal focus
- Antibody-drug conjugates
- Roche’s China deals
- Sixth since late August